Precision BioSciences (DTIL)
(Real Time Quote from BATS)
$12.06 USD
-0.14 (-1.15%)
Updated Jun 11, 2024 01:46 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
DTIL 12.06 -0.14(-1.15%)
Will DTIL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DTIL
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
Other News for DTIL
Precision BioSciences: Governance Updates and Growth Strategy
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences to Participate in Upcoming June Investor Conferences
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential